“Pasireotide as Maintenance Treatment with monthly deep intramuscular injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor”
Pasireotide inhibits growth by binding to specific receptors known as somatostatin receptors. It is approved for the treatment of Cushing’s disease and acromegaly, two conditions caused by tumors in the pituitary gland. The PAMSARC study is evaluating the drug outside its originally intended and approved indications.
Treatment lasts between 4 and 36 months. As part of the PAMSARC clinical trial, all participants are scheduled to be treated with the investigational drug pasireotide. All patients receive monthly injections of the active ingredient pasireotide into the gluteal muscles.
The study will monitor how treatment affects the time to disease progression, overall survival, and aspects of quality of life in patients.
Patient enrollment in Heidelberg is possible since April 2026.
For more information, see the Study Registry: The study is registered with the U.S. National Institutes of Health (ClinicalTrials.gov).
EudraCT-Number: 2024-511935-86-00
